Observational studyBMJ open2020
The French reporting system for drug shortages: description and trends from 2012 to 2018: an observational retrospective study.
Observational study in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Drug supply shortages and their consequences for the medical profession: a survey in Germany and Austria.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Modelling impacts of paediatric amoxicillin shortage management on pneumococcal resistance and invasive disease in Europe.Nature communications · 2026Article
- Age and sex disparities in drug shortage impacts: a 10-year nationwide study in France.European journal of public health · 2026Article
- Can a national storage obligation for medicines prevent shortages? Evidence from the Finnish experience.Exploratory research in clinical and social pharmacy · 2025Article
- Addressing Drug Shortages at Mediclinic Parkview Hospital: A Five-Year Study of Challenges, Impact, and Strategies.Cureus · 2024Article
- Advancing global antibiotic research, development and access.Nature medicine · 2024Review
- Article
- Medicine shortages in France: a 6-year retrospective study in a university medical centre.European journal of hospital pharmacy : science and practice · 2023Article
- Drug shortages in China: a cross-sectional study.BMC health services research · 2023Article
- Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience.Frontiers in public health · 2023Article
- National and transnational drug shortages: a quantitative descriptive study of public registers in Europe and the USA.BMC health services research · 2022Article
- Medicine shortages: Product life cycle phases and characteristics of medicines in short supply-A register study.Frontiers in pharmacology · 2022Article
- Patients perspectives on drug shortages in six European hospital settings - a cross sectional study.BMC health services research · 2021Article
- Observational
- Shortages Without Frontiers: Antimicrobial Drug and Vaccine Shortages Impact Far Beyond the Individual!Frontiers in medicine · 2021Article
- Drug Shortage: Causes, Impact, and Mitigation Strategies.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim was to provide figures for drug shortages in France and describe their characteristics, causes and trends between 2012 and 2018.
methodsData from the national reporting system from the Agency of Medicine and Health Product Safety (ANSM) was analysed. This database contains information regarding effective and predicted shortages of major therapeutic of interest drugs (ie, drugs whose shortage would be life-threatening or representing a loss of treatment opportunity for patients with a severe disease) which are mandatory reported by marketing authorisation holders to the ANSM. Data are presented as numbers or percentages of pharmaceutical products (ie, the product name and its formulation) reported on shortage between 2012 and 2018.
resultsThere were 3530 pharmaceutical products reported on shortage during the period, including 1833 different active substances. Drugs on shortage were mostly old products (63.4%) with national marketing authorisation procedures (62.8%), as well as injectable and oral forms (47.5% and 43.3%, respectively). Anti-infectives for systemic use ranked first (18%), followed by nervous and cardiovascular system drugs and by antineoplastic and immunomodulating agents (17.4%, 12.5% and 10.4%, respectively). The number of reported shortages presented a fourfold increase between 2012 and 2018 and a sharp rise in 2017 and 2018, along with a rise in the number of active substances on shortage. The therapeutic classes concerned remained similar over time. Manufacturing and material supply issues were the main reported reasons for the shortage each year (30%) and there was an overall rise of pharmaceutical market reasons.
conclusionDrug shortages were increasingly reported in France. Preventive measures should specifically target the products most on shortage, in particular old drugs, injectable, anti-infective, nervous system and cardiovascular system drugs as well as antineoplastic and immunomodulating agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.